A Randomized, Double-blind, Active-controlled Phase ??? Clinical Trial to Evaluate the Immunogenicity and Safety of the Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
Latest Information Update: 17 Jan 2026
At a glance
- Drugs Influenza virus vaccine quadrivalent Shanghai Institute of Biological Products (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Shanghai Institute of Biological Products
Most Recent Events
- 16 Jan 2026 New trial record